Regulation of Aeroallergen Immunity by the Innate Immune System: Laboratory Evidence for a New Paradigm

Anthony A. Horner
Departments of Medicine and Pediatrics and The Sam and Rose Stein Institute for Aging, University of California, San Diego, La Jolla, Calif., USA

Introduction

Asthma and other allergic diseases have become far more common in industrialized countries in recent decades, while atopy rates remain low in less developed countries [1–3]. Although reasons for these trends remain speculative, the rapidity with which allergic disease prevalence has increased in affected countries strongly suggests environmental factors are responsible. Adaptive responses associated with allergen tolerance and hypersensitivities appear to become imprinted early in life [4, 5]. Therefore, as infants/toddlers spend a majority of their time indoors, there is a great deal of interest in determining how home exposures impact on allergic risk.

It is generally accepted that allergen exposure is a prerequisite for sensitization and for some allergens (i.e. cockroach and house dust mite), the risk for developing hypersensitivities increases significantly when levels in the home exceed a quantifiable threshold [6–8]. However, for other allergens (i.e. dogs, cats), increased levels of home exposure appear linked to a decreased risk of sensitization, both to the allergen of interest, and to unrelated allergens [8–10]. In a recent meta-analysis of 12 relevant studies, we found the odds ratio (OR) for development of allergic stigmata during childhood was 0.83 (CI 0.73–0.96) in children raised with household pets versus those raised without them [11]. These and other findings...
suggest that aside from allergens themselves, living environments contain additional molecules that influence the immunological balance between allergen tolerance and hypersensitivity.

Endotoxin (TLR4), a molecule that activates immunocytes via TLR4, has been reported to be present at higher concentrations in homes with regular animal exposures than in homes with none [12, 13]. Moreover, in several published reports, infants raised in high endotoxin homes were found to have a reduced incidence of atopic stigmata [12, 14]. In our meta-analysis of 16 pertinent studies, the OR for allergen sensitization was 0.85 (CI 0.77–0.93) for infants raised in homes with high ambient endotoxin levels versus those raised in low levels[11]. In consideration of these relatively weak associations, it is important to recognize that endotoxin-rich environments generally contain increased levels of other immunostimulatory microbial products [15, 16]. Furthermore, several manmade pollutants promote development of allergic hypersensitivities [17]. Although, much has been learned in recent years, the molecular complexity of ambient exposures has hampered efforts to develop a holistic understanding of their impact on atopic risk. Consistent with this theme, in additional meta-analyses, living on a farm (OR 0.74, CI 0.61–0.91, n = 9), living in close proximity with livestock (OR 0.54, CI 0.36–0.81, n = 7), and unpasteurized milk consumption during the first years of life (OR 0.67, CI 0.59–0.75, n = 5) were all found to be far more negatively associated with allergic stigmata during childhood than were home endotoxin levels [11]. These meta-analyses and other epidemiological evidence strongly suggest that endotoxin levels are only one of a number of molecular variables influencing the allergic potential of homes.

**Rationale for the Study of House Dust Extract Bioactivities**

While consensus opinion supports the view that living environments have a major educational influence on developing immune systems, understanding of how ambient exposures modify allergic risk remains highly speculative. By necessity, a majority of laboratory investigations aimed at characterizing how living environments affect host immunity have made a priori assumptions about which molecules are important. As an alternative, we reasoned that the immunological ‘ether’ associated with homes might be better understood by characterizing the immunostimulatory properties of clinically relevant but unpurified environmental samples. Logic suggests that gravity concentrates immunostimulatory particulates into settled dust. Moreover, house dust allergen and endotoxin concentrations have previously been found to be predictive surrogate markers of allergic risk. Therefore, we have begun to characterize the immunostimulatory properties of sterile house dust extracts (HDEs). Studies conducted to date have yielded provocative and reproducible results, which will be the focus of this paper [18–21].

**HDEs Activate Bone Marrow-Derived Dendritic Cells**

Dust samples were collected from the bedrooms of 15 suburban homes in San Diego (California, USA) and were processed by standardized techniques, which included suspension in PBS, physical agitation and sterile filtration [19, 21]. HDEs prepared in this manner were found to elicit bone marrow-derived dendritic cell (BMDDC) cytokine production in a concentration-dependent manner. Cytokines readily detected by ELISA included IL-6 and IL-12p40 [19]. However, HDE-induced BMDDC secretion of bioactive IL-12p70 was weak compared to responses induced by ligands for TLRs 4, 7 and 9 [21]. In unpublished experiments we recently observed that HDEs induce IL-23p19 mRNA synthesis, suggesting that HDEs may preferentially promote the synthesis of bioactive IL-23, a heterodimer of IL-12p40 and IL-23p19, rather than IL-12p70. Not surprisingly, HDEs were also found to induce the upregulation of MHC class II and a variety of co-stimulatory molecules on the surface of BMDDCs.

Consistent with other studies, mean endotoxin levels of dust samples obtained from homes with pets were more than twice those of samples obtained from homes without pets [19]. Moreover, a significant correlation was found between HDE endotoxin levels and their BMDDC cytokine inducing activity. However, the correlation coefficient for this association was less than 0.6, suggesting that additional molecules contribute to the bioactivities of HDEs.

To more specifically assess the contribution of TLRs to HDE responsiveness, HDE induced cytokine production by BMDDCs prepared from wild type (WT) and TLR and MyD88 knockout (ko) mice was compared [19]. In experiments with samples derived from multiple homes, TLR4 ko BMDDCs consistently demonstrated a marked reduction in HDE (n = 10) induced cytokine production and co-stimulatory molecule expression but residual responsiveness remained. TLR2 ko BMDDCs
produced less IL-6 than WT BMDDCs but IL-12p40 production and co-stimulatory molecule expression were relatively preserved. In contrast, HDE stimulated TLR9 ko BMDDCs produced less IL-6 and IL-12p40 than WT BMDDCs. Furthermore, while TLR4 ko BMDDCs displayed a greater deficit, HDE activated TLR9 ko BMDDCs expressed lower levels of co-stimulatory molecules than WT BMDDCs. These observations support the view that TLR4, TLR2 and TLR9 independently contribute to HDE mediated BMDDC responses. In a final series of experiments, WT and MyD88 ko BMDDC responses to HDE stimulation were compared [19]. HDE stimulated MyD88 ko BMDDCs were severely compromised in their ability to respond to HDEs, although residual cytokine production and co-stimulatory molecule upregulation could be detected. These results established that MyD88 dependent signaling pathways play a central role in mediating BMDDC responsiveness to HDEs.

**HDE Adjuvant Activities**

To assess the adjuvant activities of HDEs, mice were i.n. immunized with ovalbumin (OVA) alone or with HDE (prepared from 10 separate homes), 3 times, at weekly intervals [18]. A dose of 21 μl of HDE (100mg/ml; concentration prior to filtration) was selected for these experiments, as preliminary experiments suggested that for most HDEs, this dose would provide optimal adjuvant activity. Additional control groups were i.n. immunized with OVA and Pam-3-Cys (TLR2), lipopolysaccharide (LPS; TLR4), or CpG DNA (TLR9), according to the same vaccination schedule. Mice i.n. immunized with OVA and HDE had far stronger adaptive responses, than mice i.n. immunized with OVA alone, establishing that HDEs have mucosal adjuvant activities. In addition, HDEs used in these studies were consistently found to act as Th2-biasing adjuvants, as they induced strong allergen-specific IgE and Th2 polarized cytokine responses but weak IgG2a and IFNγ responses. Moreover mice immunized with OVA and HDEs consistently developed an eosinophil-rich airway inflammatory response and increased bronchial responsiveness to methacholine after i.n. OVA challenge [18]. Finally, most HDEs were found to be more effective at inducing OVA-specific, Th2-biased, airway hypersensitivities than Pam-3-Cys and low-dose LPS, both of which have previously been described as Th2 adjuvants [18, 22].

Consistent with previously discussed BMDDC studies, the adjuvant activities of HDEs were found to be dependent on signaling through MyD88 [18], further evidence of their relative dependence on signaling through TLRs. However, this evidence remains inconclusive, given that IL-1 and IL-18 signaling are also MyD88 dependent [23]. Therefore, this result could also reflect the importance of these cytokines in mediating the adjuvant activities of HDEs. Additional studies will be required to resolve this issue. Nonetheless, these experimental results challenge the commonly held belief that microbial products in general, and TLR ligands in particular, protect against the allergic march by inherently favoring the development of Th1-biased immune profiles. These findings might also lead one to wonder why mice and humans are not universally compromised by aeroallergen hyper-sensitivities.

**HDE Tolerogenic Activities**

The experiments just discussed might be construed to suggest that many, if not all, living environments intrinsically promote the development of allergic asthma. However, in these studies mice were airway exposed to the immunostimulatory contents of HDEs at weekly intervals and at levels likely to be in great excess of daily physiological exposures. In contrast, individuals are thought to inhale air laced with far lower concentrations of immunostimulatory molecules on a semi-continuous basis [24]. Therefore, additional experiments were designed to better model real-world exposures. First a HDE standard (HDEst) was prepared from individual HDEs with high levels of adjuvant activity. Mice received 3 weekly i.n. OVA immunizations, as in previously described experiments. HDEst was delivered i.n. weekly with OVA, or daily in low doses (1/7th weekly dose, 3 μl; beginning 1 week before the first and ending with the last dose of OVA, as in previously discussed experiments), or both daily and weekly [18].

Daily i.n. HDEst delivery had little adjuvant effect on OVA-specific responses. More importantly, this delivery schedule prevented mice concurrently receiving weekly i.n. OVA and HDEst (adjuvant dose) from developing both Th2-biased adaptive responses and experimental asthma [18]. In additional unpublished studies we determined whether weekly i.n. OVA vaccination in conjunction with daily HDEst delivery would induce long lasting allergen specific tolerance. In these studies mice received a series of 3 weekly i.n. OVA vaccinations either alone, with weekly adjuvant doses of HDE (21 μl), or in conjunction with daily low-dose HDEst (3 μl) delivery, as...
just described. One month after the last of the primary OVA immunizations, all mice were OVA sensitized by weekly i.n. OVA/adjuvant dose HDEst delivery on 3 occasions. Mice receiving i.n. OVA and daily HDEst during primary immunizations were found to be highly resistant to Th2 sensitization, while mice in other primary immunization groups (nothing, OVA alone or weekly OVA plus HDEst) were not. In additional studies, we established that both the Th2 adjuvant and tolerogenic activities of HDEst could be replicated with purified LPS. To our knowledge, these are the first experiments to directly establish that stimulants of innate immunity, which are traditionally considered to be adjuvants, when used under distinct experimental conditions, can also serve as potent inducers of antigen tolerance.

Modulatory Influence of HDE on the Th2-Biased Airway Hypersensitivity Response

Along with infants developing primary allergen-specific immunity (hypersensitivity vs. tolerance), airway exposures to stimulants of innate immunity are likely to impact greatly on the clinical status of patients with pre-existing allergic respiratory diseases. Therefore, we determined how bolus and daily i.n. delivery of HDEst modified the aeroallergen challenge responses of previously Th2-sensitized mice [20]. One group of mice received a high-dose HDEst bolus concurrently with each i.n. OVA challenge. Another group of mice received low dose i.n. HDEst (1/7th bolus dose) on a daily basis beginning 7 days before the first and ending with the final OVA challenge. Somewhat surprisingly, both daily and bolus i.n. HDEst delivery attenuated features of the airway hypersensitivity response, but daily delivery was significantly more effective. Moreover, daily but not bolus HDEst delivery attenuated bronchial lymph node mononuclear cell cytokine responses to in vitro OVA stimulation and partially desensitized mice to additional airway challenges a month later with OVA alone.

Similar to daily i.n. HDEst delivery, daily i.n. LPS delivery was found to attenuate the airway hypersensitivity response of Th2 sensitized mice undergoing airway allergen challenge [20]. However, unlike many other comparative studies in which HDE and LPS were found to have similar bioactivities, in Th2 sensitized mice undergoing airway allergen challenge, concurrent bolus delivery of HDEst and LPS had divergent effects. As previously mentioned, bolus HDEst delivery attenuated the airway hypersensitivity response, while with LPS, the airway inflammatory response was augmented [20]. In a final series of experiments, daily i.n. HDEst delivery was found to efficiently attenuate the airway hypersensitivity response of previously Th2-sensitized TLR4-deficient mice undergoing concurrent allergen challenge. Taken together, these observations demonstrate that endotoxin does not completely recapitulate, nor is it completely responsible for the immunomodulatory potential of living environments.

Conclusions

Investigations reviewed in this paper demonstrate that pulmonary exposures to allergen non-specific immunostimulants ubiquitous in indoor living environments have the potential to impact significantly on allergic risk. Nonetheless, understanding of the molecular variables and immunological mechanisms responsible is far from complete. Correlations between pet, farm, animal, unpasteurized milk and endotoxin exposures during childhood and a reduced incidence of allergic manifestations have been found in some studies but these trends have been inconsistently reported, and in select studies associations were relatively weak, nonexistent or reversed [11]. Moreover, results from the many epidemiological studies conducted to date provide little insight into the cellular and molecular mechanisms by which living environments influence allergic risk.

Although ubiquitous, concentrations of TLR ligands and other stimulants of innate immunity in the ambient air of most micro-environments are thought to be very low. For example, one study of pediatric exposure calculated that the median amount of endotoxin inhaled by children each day is from 46 to 220 pg [24]. However, endotoxin can be readily detected in essentially all air samples tested and concentrations can vary by as much as 5 logs [24, 25]. Given this lack of homogeneity, estimates of daily exposure based on air sampling are unlikely to account for episodic periods of exposure to air containing extremely high concentrations of endotoxin and/or other immunostimulants of microbial origin. Moreover, despite evidence that living environments contain a wide range of molecules that induce innate immune activation, the only assay commercially available for their detection at a molecular level is the limulus lysate assay for endotoxin. This deficiency in assays for the detection of molecules with immunostimulatory potential is a major impediment for efforts aimed at characterizing how living environments affect allergic risk.
As an alternative to measuring concentrations of immunostimulatory molecules in HDEs our research group has used well-defined bioassays and animal models of allergic disease to better characterize the bioactivities of HDEs and the living environments they represent. In vitro studies have shown that TLRs play a central role in dendritic cell responsiveness to the allergen non-specific immunostimulatory contents of unpurified HDEs and the living environments they represent [19, 21]. Additional i.n. vaccination experiments have revealed that weekly airway exposures to adjuvant doses of HDEs induce Th2-biased airway hypersensitivities to co-administered allergens, as commonly suggested in the literature. Instead, these findings suggest that living environments have far greater potential to promote tolerogenic and/or Th2-biased immune responses, depending on additional variables [18–20]. These are likely to include the relative and absolute concentration of each individual immunostimulant contained in inspired air during the course of the day, and in particular, the frequency and duration of exposures to air laced with high concentrations of these immunostimulants. The observation that molecules that activate dendritic cells and act as mucosal adjuvants (i.e. HDEs and LPS) also function as tolerogenic agents is novel and likely to be of great clinical significance. However, while mechanistic studies are ongoing, current understanding of this phenomenon is limited and based principally on indirect evidence.

Along with attenuating the adjuvant activities of HDEs, we found that the innate airway inflammatory response that develops 24 h after i.n. bolus HDE challenge (neutrophilic inflammation and cytokine release) can be inhibited by pre-treating mice with daily i.n. low dose HDE [18]. This phenomenon of reduced responsiveness with repetitive exposure has previously been described with LPS and other TLR ligands, and is commonly referred to as LPS tolerance [26–28]. In unpublished studies we further observed that daily i.n. HDE delivery led to significant increases in local mRNA expression for molecules that mediate LPS tolerance (IL-10, STAT3, IRAK, SHIP) [26, 28–30] when compared to bolus i.n. HDE delivery. These observations may explain why human lungs remain un-inflamed despite the continuous inhalation of air laced with stimulants of innate immunity [31]. These preliminary findings also provide evidence that mechanisms associated with the regulation of innate immunity (LPS tolerance) might contribute to the tolerogenic influence of daily i.n. HDE/LPS delivery on allergen specific immunity.

Over the last several years, our laboratory has characterized the immunostimulatory potential of homes, using HDEs as a surrogate material for investigations presented herein [18–21]. These studies lead us to conclude that TLRs play a central role in mediating responses to immunostimulants that are ubiquitous indoors. However, in urban environments, diesel exhaust and other pollutants of human origin are likely to be found at far higher concentrations out of doors and these molecules are known to perturb immune homeostasis, at least in part, by creating oxidant stress, a phenomenon that is uniquely receptor independent [17]. Several laboratories have begun to investigate the immunostimulatory potential of unpurified samples of particulate matter (APM) prepared from outdoor air [32–35]. Moreover, Williams et al. [32] have already published that APM has MyD88 independent immunostimulatory properties. Given these considerations, it will be important to compare the immunostimulatory properties of APM and diesel exhaust particulates with those of HDEs in future experiments.

While much remains to be learned of the molecular and immunostimulatory content of inhaled air, experimental results discussed in this article lead us to propose a new paradigm by which ambient exposures might modulate innate immune homeostasis in the airways, promote the development of aeroallergen tolerance or hypersensitivity, and modify the respiratory status of previously aeroallergen-sensitized patients. The tenets of this model (fig. 1) are as follows. (1) Basal levels of exposure to endotoxin and other immunostimulatory materials present in ambient air are generally not sufficient to provoke an inflammatory reaction in the airways or to provide adjuvant activity for co-inspired aeroallergens. (2) Physiological exposures to ambient air laced with low but adequate concentrations of TLR ligands and other immunostimulatory molecules leads to a state of relative airway hypo-responsiveness to these molecules and potentially other immunostimulants. (3) Airways receiving inadequate innate immune stimulation remain far more

Regulation of Aeroallergen Immunity by the Innate Immune System

J Innate Immun 2010;2:107–113

111
responsive to airborne immunostimulants than airways that are regularly exposed to these molecules. (4) If dampening by basal immunostimulant exposures is inadequate, episodic exposures to ambient air laced with super-physiologic concentrations of these molecules have the potential to provide Th2 adjuvant activity for the development of hypersensitivities to co-inspired aeroallergens. Although far from proven, the model presented in figure 1 is testable and consistent with current understanding of the regulation of innate and adaptive immunity in the airways. In addition, this paradigm provides a rational mechanistic framework for understanding why semi-continuous airway exposures to aeroallergens and molecules that activate innate immunity only prime a subset of individuals to develop Th2-biased allergic respiratory diseases, while a majority become aeroallergen tolerant and their airways remain not inflamed. In the years to come, the continued study of the interface between host immunity and the environment will give rise to a far more comprehensive understanding of the genesis of allergic respiratory diseases and other diseases of immune dysregulation and ultimately, may lead to the development of better therapeutic strategies for their prevention and treatment.

Acknowledgments

This work was supported by grant AI61772 from the National Institutes of Health.

References

2 Braman SS: The global burden of asthma. Chest 2006;130:4–125.
Regulation of Aeroallergen Immunity by the Innate Immune System

